DoD Prostate Cancer, Clinical Consortium Award

By Dept. of the Army -- USAMRAA
Government Grant





The Clinical Consortium Award mechanism provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute phase 2 or phase 2-linked phase 1 (phase 1/2) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer as pertaining to the FY21 PCRP Overarching Challenges. Support from this award is directed toward consortium infrastructure needs rather than direct support of the research itself.The principal goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of the disease. To facilitate global investigations, Principal Investigators (PIs) from both U.S. and international institutions are encouraged to apply. Submissions from institutions with enh...

Thanks to the funder for their generosity.